Autoimmune diseases (ADs) are a collection of immunological disorders in which the immune system responds to self-antigens by producing autoantibodies or self-sensitized cells. Current treatments are unable to cure ADs, and achieving long-term drug-free remission remains a challenging task. Hematopoietic stem cell transplantation (HSCT) stands out from other therapies by specifically targeting ADs that target various cell subpopulations, demonstrating notable therapeutic benefits and resulting in sustained drug-free remission. Since different ADs have distinct mechanisms of action, the comprehensive understanding of how HSCT works in treating ADs is crucial. This review provides a detailed overview of the latest research and clinical applications of HSCT in treating ADs, offering new insights for clinicians aiming to optimize its use for ADs management.
Steroid-refractory gut acute graft-versus-host disease (SR-Gut-aGVHD) is the major cause of nonrelapse death after allogeneic hematopoietic cell transplantation. High numbers of donor-type IL-22+ T cells, IL-22-dependent dysbiosis, and loss of antiinflammatory CX3CR1hi mononuclear phagocytes (MNPs) play critical roles in SR-Gut-aGVHD pathogenesis. CEACAM1 on intestinal epithelial cells (IECs) is proposed to regulate bacterial translocation and subsequent immune responses in the intestine. Here, with imaging mass cytometry (IMC), combined scRNA-Seq with ATAC-Seq, and high-dimensional flow cytometry analysis, we show that CEACAM1 expression was enhanced on IECs in murine and human SR-Gut-aGVHD. Ceacam1 deficiency on host IECs effectively prevented SR-Gut-aGVHD in murine models. Ceacam1 deficiency on IECs resulted in (i) higher numbers of IL-22+IL-10+Foxp3+CD4+ peripheral Tregs (pTregs) and lower numbers of conventional IL-22+CD4+ T (Tcon), Th/Tc1, and Th17 cells in the intestine; (ii) higher prevalence of beneficial commensal bacteria that augment colonic pTreg expansion, with lower prevalence of pathogenic bacteria; and (iii) higher numbers of antiinflammatory CD103-CX3CR1hi MNPs that produce indoleamine 2,3-dioxygenase (IDO) and IL-10, with lower numbers of proinflammatory CD103+CX3CR1lo MNPs that produce IL-6. Thus, specifically targeting IEC CEACAM1 represents a promising approach for prevention of SR-Gut-aGVHD.
Chronic graft-versus-host disease (cGVHD) is one of the leading causes of mortality following allogeneic hematopoietic stem cell transplantation (HSCT), with only 50 % of patients responding to conventional corticosteroids with or without calcineurin inhibitors. Monoclonal antibodies (mAbs), such as CD20 mAbs, are the first drugs to demonstrate greater efficacy than corticosteroids in first-line treatment of cGVHD. This review provides a comprehensive overview of recent developments in the clinical utilization of mAbs to prevent and treat cGVHD. We also describe the application of drugs with target sites that are identical to or linked to those of cGVHD in autoimmune diseases as potential future treatments for cGVHD. In summary, we collected known evidence concerning the clinical research progress on the use of mAbs in the prevention and treatment of cGVHD and identified drugs with the same target sites in autoimmune diseases for potential future applications in cGVHD, with the goal of providing suggestions and inspiration for optimizing cGVHD treatment strategies and research directions.
Background: Acute graft-versus-host disease (aGVHD) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The development of methods that preserve graft-versus-leukemia (GVL) activity while preventing aGVHD remains a long-sought goal. Recent studies suggest that mesenchymal stem cells (MSCs), particularly human umbilical cord-derived MSCs (HUC-MSCs), are effective at mitigating aGVHD, yet their varied efficacy remains poorly understood. Methods: We performed a comprehensive analysis of MSCs heterogeneity through single-cell transcriptomic mapping across nine human tissue sources and identified the keratin 8 high-expression (KRT8 + ) subpopulation of HUC-MSCs with enhanced functional properties. We further validated the functional roles of the KRT8 + subpopulation through lentivirus-mediated KRT8 overexpression. Bulk RNA sequencing was used to analyze the genomic impact of KRT8 overexpression. Additionally, we examined the effects of KRT8 overexpression on cellular senescence via Western blotting and β-galactosidase (SA-β-gal) staining. The immunosuppressive function of HUC-MSCs was evaluated by coculturing them with CD3 + T cells and liver organoids. Cell migration ability was assessed through Transwell assays and PKH26 dye labeling in vivo . An MHC-mismatched GVHD mice model (C57BL/6J to BALB/c) was established to test the therapeutic effect of HUC-MSCs. Clinical signs of aGVHD were monitored, and pathological changes were analyzed using hematoxylin and eosin staining. The GVL effect was evaluated through the inoculation of luciferase-transfected A20 cells and bioluminescence imaging. Results: KRT8 was expressed predominantly in HUC-MSCs. Compared with the KRT8 low-expression (KRT8 lo ) subpopulation of HUC-MSCs, the KRT8 + subpopulation presented increased stemness and reduced immunogenicity. KRT8 overexpression in HUC-MSCs significantly ameliorated aGVHD in vivo . Importantly, increased KRT8 expression in HUC-MSC did not impaire GVL activity in A20 lymphoma cells. Functional experiments further confirmed that HUC-MSCs with increased KRT8 expression significantly reduced cellular senescence by increasing enhancer of zeste homolog 2 ( EZH2 )-mediated histone h3 lysine 27 trimethylation (H3K27me3). This upregulation resulted in increased secretion of hepatocyte growth factor (HGF). This, in turn, suppressed T-cell proliferation and activation, significantly reducing liver organoid damage in vitro . Conclusions: Our results suggest that the infusion of KRT8 + HUC-MSCs enhances the efficacy of preventing aGVHD but does not interfere with the GVL effect. This strategy represents a promising therapeutic advancement in the setting of allo-HSCT.